Warning: mkdir(): Permission denied in /data/Websites/newwiki-mpm/fuel/core/classes/log.php on line 122

Warning!

ErrorException [ Warning ]: mkdir(): Permission denied

COREPATH/classes/log.php @ line 122:

121:	
122:	mkdir($filepath, \Config::get('file.chmod.folders', 0777), true);
123:	umask($old);
JAK1 - Wiki-MPM

Search Results for: JAK1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel ANKRD13C ankyrin repeat domain 13C
Novel CBR1 carbonyl reductase 1
  • Synthesis of Prostaglandins (PG) and Thromboxanes (TX)
  • Rutin
  • Resveratrol
  • Heptaethylene glycol
  • 2-(2-{2-[2-(2-{2-[2-(2-Ethoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol, Polyethyleneglycol Peg400
  • Quercetin
  • 3-(4-Amino-1-Tert-Butyl-1h-Pyrazolo[3,4-D]Pyrimidin-3-Yl)Phenol
  • Curcumin
  • Curcumin sulfate
Novel DAB1 DAB adaptor protein 1
  • Reelin signalling pathway
Novel DHX9 DExH-box helicase 9
  • RIP-mediated NFkB activation via ZBP1
  • DEx/H-box helicases activate type I IFN and inflammatory cytokines production
  • mRNA Splicing - Major Pathway
Novel NFYC nuclear transcription factor Y subunit gamma
  • PPARA activates gene expression
  • Activation of gene expression by SREBF (SREBP)
  • Activation of gene expression by SREBF (SREBP)
  • ATF4 activates genes in response to endoplasmic reticulum stress
  • ATF6 (ATF6-alpha) activates chaperone genes
  • ATF6 (ATF6-alpha) activates chaperone genes
  • FOXO-mediated transcription of cell death genes
Novel P2RY1 purinergic receptor P2Y1
  • G alpha (q) signalling events
  • P2Y receptors
  • ADP signalling through P2Y purinoceptor 1
  • ADP signalling through P2Y purinoceptor 1
  • Promethazine
Novel P3H1 prolyl 3-hydroxylase 1
  • Collagen biosynthesis and modifying enzymes
  • Ascorbic acid
  • Proline
  • Osteogenesis imperfecta
Novel VNN2 vanin 2
  • Post-translational modification: synthesis of GPI-anchored proteins
  • Vitamin B5 (pantothenate) metabolism
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate WASPs and WAVEs
  • HDR through Single Strand Annealing (SSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Cyclin D associated events in G1
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • RUNX2 regulates osteoblast differentiation
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • ATP
  • Imatinib
  • Dasatinib
  • N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
  • Nilotinib
  • XL228
  • Bosutinib
  • 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
  • Myristic acid
  • PD-166326
  • 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
  • 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
  • Regorafenib
  • Ponatinib
  • Fostamatinib
  • Brigatinib
  • Radotinib
  • Chronic myeloid leukemia (CML)
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
AGTR1 angiotensin II receptor type 1
  • Peptide ligand-binding receptors
  • G alpha (q) signalling events
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • Valsartan
  • Olmesartan
  • Losartan
  • Candesartan cilexetil
  • Eprosartan
  • Telmisartan
  • Irbesartan
  • Forasartan
  • Saprisartan
  • Tasosartan
  • CYT006-AngQb
  • Azilsartan medoxomil
  • Fimasartan
  • Angiotensin II
  • Candesartan
  • Renal tubular dysgenesis
BRCA1 BRCA1 DNA repair associated
  • Meiotic synapsis
  • SUMOylation of DNA damage response and repair proteins
  • HDR through Single Strand Annealing (SSA)
  • HDR through Homologous Recombination (HRR)
  • Metalloprotease DUBs
  • Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Resolution of D-loop Structures through Holliday Junction Intermediates
  • Nonhomologous End-Joining (NHEJ)
  • Homologous DNA Pairing and Strand Exchange
  • Processing of DNA double-strand break ends
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • TP53 Regulates Transcription of DNA Repair Genes
  • Regulation of TP53 Activity through Phosphorylation
  • G2/M DNA damage checkpoint
  • Transcriptional Regulation by E2F6
  • Meiotic recombination
  • Defective DNA double strand break response due to BRCA1 loss of function
  • Defective DNA double strand break response due to BARD1 loss of function
  • Breast cancer
  • Ovarian cancer
BTK Bruton tyrosine kinase
  • ER-Phagosome pathway
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • Regulation of actin dynamics for phagocytic cup formation
  • DAP12 signaling
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • G alpha (q) signalling events
  • G alpha (12/13) signalling events
  • MyD88 deficiency (TLR2/4)
  • IRAK4 deficiency (TLR2/4)
  • RHO GTPases Activate WASPs and WAVEs
  • G beta:gamma signalling through BTK
  • FCGR3A-mediated phagocytosis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Dasatinib
  • Inositol 1,3,4,5-Tetrakisphosphate
  • XL418
  • Ibrutinib
  • Acalabrutinib
  • Fostamatinib
  • Zanubrutinib
  • Abivertinib
  • Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
  • Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD)
CCR1 C-C motif chemokine receptor 1
  • Chemokine receptors bind chemokines
  • G alpha (i) signalling events
  • Interleukin-10 signaling
CCR5 C-C motif chemokine receptor 5
  • Binding and entry of HIV virion
  • Chemokine receptors bind chemokines
  • G alpha (i) signalling events
  • Interleukin-10 signaling
  • Maraviroc
  • AMD-070
  • CCR5 mAb
  • Leronlimab
  • Aplaviroc
  • Vicriviroc
  • Ibalizumab
  • INCB-9471
CSF2RB colony stimulating factor 2 receptor subunit beta
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RAF/MAP kinase cascade
  • Surfactant metabolism
  • Defective CSF2RB causes SMDP5
  • Defective CSF2RA causes SMDP4
  • Interleukin receptor SHC signaling
  • Sargramostim
  • NPI 32101
  • Resatorvid
CSF3R colony stimulating factor 3 receptor
  • Other interleukin signaling
  • Transcriptional regulation of granulopoiesis
  • Pegfilgrastim
  • Filgrastim
  • FavId
  • Lenograstim
  • Lipegfilgrastim
CXCR4 C-X-C motif chemokine receptor 4
  • Binding and entry of HIV virion
  • Signaling by ROBO receptors
  • Chemokine receptors bind chemokines
  • G alpha (i) signalling events
  • Framycetin
  • AMD-070
  • Plerixafor
  • Ibalizumab
  • Chemokine receptor defect, including the following disease: WHIM syndrome
EIF2AK2 eukaryotic translation initiation factor 2 alpha kinase 2
  • ISG15 antiviral mechanism
  • Inhibition of PKR
  • Fostamatinib
ELP2 elongator acetyltransferase complex subunit 2
  • HATs acetylate histones
ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
  • Choriocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Bladder cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Cholangiocarcinoma
  • Breast cancer
  • Cervical cancer

Page 1 out of 4 pages